Showing results (361-370 of 1,988) with videos related to

Sort By:
Pageof 199
Prostate Cancer and Prostatic Diseases|January 31, 2019
Allopurinol and the risk of prostate cancer in a Finnish population-based cohortVille Kukko, Antti Kaipia, Kirsi Talala, et al.
Prostate Cancer and Prostatic Diseases|September 26, 2020
Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studiesOliver Brunckhorst, Safiya Hashemi, Anastasia Martin, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2020
Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse modelWilhelmina C M Duivenvoorden, Magda Naeim, Sarah N Hopmans, et al.
Prostate Cancer and Prostatic Diseases|January 5, 2020
Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatmentSara M Falzarano, Yaw A Nyame, Jesse K McKenney, et al.
Prostate Cancer and Prostatic Diseases|January 15, 2020
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcomeSalma Meziou, Cassandra Ringuette Goulet, Hélène Hovington, et al.
Prostate Cancer and Prostatic Diseases|August 30, 2020
The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysisAshley Bigaran, Eva Zopf, Jason Gardner, et al.
Prostate Cancer and Prostatic Diseases|August 30, 2020
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analysesHsiang Ying Lee, Hsiao-Ling Chen, Jeremy Yuen-Chun Teoh, et al.
Prostate Cancer and Prostatic Diseases|October 3, 2020
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamideNaomi B Haas, Michael J LaRiviere, Thomas H Buckingham, et al.
Prostate Cancer and Prostatic Diseases|January 16, 2019
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registryEdoardo Francini, Kathryn P Gray, Grace K Shaw, et al.
Prostate Cancer and Prostatic Diseases|January 22, 2019
Exploring the risk-reward balance in focal therapy for prostate cancer-a contribution to the debateAnouck Kluytmans, Jurgen J Fütterer, Mark Emberton, et al.
Pageof 199